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Introduction
Immune checkpoint blockade (ICB), which
targets the inhibitory immune checkpoints
on the T cells, has recently revolutionized
cancer treatment. ICB works by introducing
antibody, such as anti-PD1 and anti-CTLA,
that can bind to the inhibitory molecules on
CD8+ T cells in cancer patients. Upon
binding to the targets such as PD1 and
CTLA4, the inhibitory signals on the T cells
are removed, which reinvigorates the T
cells anti-tumor functions. ICB has been
shown to induce favorable and long-lasting
anti-tumor response in many cancer types
including bladder cancer. However, only
around 30% of bladder cancer patients
respond to ICB, highlighting the urgent
need to understand the resistance
mechanisms to ICB and improve its efficacy
to benefit more cancer patients.

Hypothetical Tumor Growth Curve

Figure 2. In vivo CRISPR knockout screen identified 50
genes as potential targets for improving ICB. Cells with
HADH knockout were enriched under anti-PD1 selective
pressure, suggesting that knocking out HADH can
confer cancer cell resistance to ICB.

Fig 5. Mice were injected with either HADHOE or wild type
tumor cells, followed by treatment with anti-PD1 or PBS
on day 3, 6 and 9 post tumor inoculation. Tumor growth
will be measured every 3 days. Animal survival will also
be monitored.

Results

Figure 8. Hypothetical tumor growth curve. Mice injected
with HADHOE tumor cells and treated with α-PD1 are
expected to have smaller tumors after treatment. Mice
injected with wild type tumor cells and IgG/PBS are
expected to have larger tumors. Tumor sizes for the
remaining groups are expected to be similar and to vary in
size.

Conclusions
We successfully established a mouse
bladder cancer cell line with HADH
overexpression. We expect to find that
overexpressing HADH can delay tumor
growth and improve animal survival when
combined with anti-PD1 treatment.

Future Directions
More experiments can be done in vitro to
analyze ferroptosis, levels of NAD, and
levels of ROS to better understand how
overexpression of HADH affects each
process or type of molecule.

Figure 1. Current immune checkpoint inhibitors(anti-PD1,
anti-CTLA4, and anti-PD-L1) bind to the receptors to
mount an anti-tumor response.

Hypothesis
To systemically investigate the resistance
mechanisms to ICB and explore the
potential targets that can improve ICB
efficacy, Dr. Sharma’s lab has previously
performed an in vivo CRISPR knockout
screen and identified a list of 50 genes
which can modulate a tumor’s response to
ICB. One of the genes is HADH, which
encodes 3-hydroxyacyl-CoA
dehydrogenase and catalyzes the third
step in beta oxidation. During lipid beta
oxidation, NADH is produced and used by
mitochondria oxidative phosphorylation
(OXPHOS) to provide ATP for the tumor
cells. Enhanced OXPHOS has been
shown to promote lipid oxidation, which
can sensitize tumor cells to a type of cell
death called ferroptosis. Based on our
preliminary data that HADH knockout
conferred tumor cell resistance to ICB, we
hypothesize that HADH expression affects
response to ICB by affecting beta
oxidation, production of ROS, lipid
peroxidation, and CD8 T cell induced
ferroptosis.
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Figure 3. Project hypothesis. HADH activity affects
response to ICB by affecting beta oxidation, synthesis of
ROS, lipid peroxidation, and response to ferroptosis.

Materials and Methods

Figure 6. qPCR analysis of HADH overexpression shows
that the HADH overexpression cell line had a 16-fold
change in transcription level compared to wild type cells.
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Figure 4. An HADHOE plasmid was transfected into MB49
cells, a mouse urothelial carcinoma cell line.
Overexpression of the gene was analyzed by conducting
qPCR and a Western blot.

Figure 7. Western blot analysis of HADH expression
shows successful transfection of HADH overexpression
plasmid into MB49 cells.
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